CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A) vs. mFOLFIRINOX plus placebo (Arm B) in 94 subjects with advanced pancreatic cancer, not amenable to curative treatment. Both ar...
Phase 2
Indianapolis, Indiana, United States and 7 other locations
phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety pr...
Phase 1
Indianapolis, Indiana, United States and 44 other locations
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors...
Phase 2
Indianapolis, Indiana, United States and 71 other locations
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Phase 1
Indianapolis, Indiana, United States and 22 other locations
the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients with RAS or RAF or NF-1 mutated ...
Phase 1
Indianapolis, Indiana, United States and 5 other locations
irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI) for treatment of patients with locally advanced pancreatic...
Phase 2
Indianapolis, Indiana, United States and 3 other locations
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific gen...
Phase 1, Phase 2
Indianapolis, Indiana, United States and 49 other locations
deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors.This study will consist of Part 1 which includes 7 cohorts of: uroth ...
Phase 2
Muncie, Indiana, United States and 120 other locations
and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two ...
Phase 1
Indianapolis, Indiana, United States and 14 other locations
with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key proteins of the RAS/RAF/MEK/ERK pathwa...
Phase 1, Phase 2
Indianapolis, Indiana, United States and 19 other locations
Clinical trials
Research sites
Resources
Legal